No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TCBK TriCo Bancshares
- 37.790
- +0.640+1.72%
Trading May 7 10:53 ET
1.25BMarket Cap11.52P/E (TTM)
37.790High37.230Low7.40KVolume37.230Open37.150Pre Close277.66KTurnover0.02%Turnover Ratio10.74P/E (Static)33.17MShares45.40752wk High1.08P/B1.20BFloat Cap28.87352wk Low1.23Dividend TTM31.67MShs Float55.935Historical High3.25%Div YieldTTM1.51%Amplitude5.426Historical Low37.547Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
KBW Gives a Hold Rating to Trico Bancshares (TCBK)
Express News | Trico Bancshares : Raymond James Cuts Target Price to $38 From $40
KBW Sticks to Their Hold Rating for Trico Bancshares (TCBK)
TriCo Q1 2024 GAAP EPS $0.83 Beats $0.80 Estimate, Sales $98.507M Miss $100.039M Estimate
TriCo (NASDAQ:TCBK) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.80 by 3.75 percent. This is a 22.43 percent decrease over earnings of $1.07 per share
Earnings Flash (TCBK) TRICO BANCSHARES Posts Q1 Revenue $82.7M
07:36 AM EDT, 04/25/2024 (MT Newswires) -- Earnings Flash (TCBK) TRICO BANCSHARES Posts Q1 Revenue $82.7M
TriCo Bancshares (TCBK) Surpasses Analyst Expectations in Q1 2024 Earnings
Comments
Insider transactions indicate confidence in the company's future, with purchases made at prices near the current one. The level of insider ownership suggests a reasonable alignment with the company's interests.
One TriCo Bancshares Insider Raised Their Stake In The Previous Year
Upgrades
• $Arcturus Therapeutics(ARCT.US$ : Baird Upgrades to Neutral from Underperform - PT $18 (from $21)
• $Arrowhead Pharmaceuticals(ARWR.US$ : Baird Upgrades to Outperform from Neutral - PT $60 (from $71)
• $Cronos Group(CRON.US$ : CIBC Upgrades to Outperformer from Neutral
• $HF Sinclair(DINO.US$ : Cowen Upgrades to Outperform from Market Perform - PT $52 (from $38)
• $8x8(EGHT.US$ : B. Riley Upgrades to Buy from Neutral - PT $13.50
• $Novanta(NOVT.US$ : William...
• $Arcturus Therapeutics(ARCT.US$ : Baird Upgrades to Neutral from Underperform - PT $18 (from $21)
• $Arrowhead Pharmaceuticals(ARWR.US$ : Baird Upgrades to Outperform from Neutral - PT $60 (from $71)
• $Cronos Group(CRON.US$ : CIBC Upgrades to Outperformer from Neutral
• $HF Sinclair(DINO.US$ : Cowen Upgrades to Outperform from Market Perform - PT $52 (from $38)
• $8x8(EGHT.US$ : B. Riley Upgrades to Buy from Neutral - PT $13.50
• $Novanta(NOVT.US$ : William...
15
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg